Tumor-associated macrophages as a prognostic parameter in multiple myeloma

Annals of Hematology

Volumn 92, Issue 5, 2013, Pages 669-677

  Suyanı, Elif ^a   Sucak, Gülsan Türköz ^a   Akyürek, Nalân ^a   Şahin, Sevinç ^a   Baysal, Nuran Ahu ^a   Yağcı, Münci ^a   Haznedar, Rauf ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

CD163; CD68; Multiple myeloma; Prognosis; Tumor associated macrophage

Indexed keywords

BLOOD CLOTTING FACTOR 8; BORTEZOMIB; CD163 ANTIGEN; CD68 ANTIGEN; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISOLONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGE; AGED; BONE MARROW; BONE MARROW STROMA; CANCER GRADING; CANCER PROGNOSIS; CAPILLARY DENSITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STROMA; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84877922873     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1652-6     Document Type: Review

References (47)

1. Podar K, Chauhan D, Anderson KC (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23:10-24
2. Mitsiades CS, Mitsiades NS, Munshi NC et al (2006) The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 42:1564-1573
3. Mitsiades CS, Mitsiades NS, Richardson PG et al (2007) Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 101:950-968
4. Jakob C, Sterz J, Zavrski I et al (2006) Angiogenesis in multiple myeloma. Eur J Cancer 42:1581-1590
5. Vacca A, Ribatti D (2006) Bone marrow angiogenesis in multiple myeloma. Leukemia 20:193-199
6. Rajkumar SV, Leong T, Roche PC et al (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6:3111-3116
7. Anderson KC (2007) Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol 35(4 Suppl 1):155-162
8. Anderson KC (2011) New insights into therapeutic targets in myeloma. Hematology Am Soc Hematol Educ Program 2011:184-190
9. Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22:231-237
10. Mantovani A (2011) B cells and macrophages in cancer: yin and yang. Nat Med 17:285-286
11. Allavena P, Sica A, Solinas G et al (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66:1-9
12. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11:889-896
13. Zheng Y, Cai Z, Wang S et al (2009) Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114:3625-3628
14. Bartl R, Frisch B, Fateh-Moghadam A et al (1987) Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 87:342-355
15. Andjelic B, Mihaljevic B, Todorovic M et al (2012) The number of lymphoma-associated macrophages in tumor tissue is an independent prognostic factor in patients with follicular lymphoma. Appl Immunohistochem Mol Morphol 20:41-46
16. Ruffell B, Affara NI, Coussens LM (2012) Differential macrophage programming in the tumor microenvironment. Trends Immunol 33:119-126
17. Sica A, Larghi P, Mancino A et al (2008) Macrophage polarization in tumour progression. Semin Cancer Biol 18:349-355
18. Ch'ng ES, Jaafar H, Tuan Sharif SE (2011) Breast tumor angiogenesis and tumor-associated macrophages: histopathologist's perspective. Patholog Res Int 2011:572706
19. Leek RD, Lewis CE, Whitehouse R et al (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56:4625-4629
20. Mahmoud SM, Lee AH, Paish EC et al (2012) Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 65:159-163
21. Zhang B, Yao G, Zhang Y et al (2011) M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo) 66:1879-1886
22. Nonomura N, Takayama H, Nakayama M et al (2011) Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int 107:1918-1922
23. Shimura S, Yang G, Ebara S et al (2000) Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 60:5857-5861
24. Shirabe K, Mano Y, Muto J et al (2012) Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today 42:1-7
25. Ding T, Xu J, Wang F et al (2009) High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol 40:381-389
26. Hanada T, Nakagawa M, Emoto A et al (2000) Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 7:263-269
27. Forssell J, Oberg A, Henriksson ML et al (2007) High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 13:1472-1479
28. Kurahara H, Shinchi H, Mataki Y et al (2011) Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 167:211-219
29. Bronkhorst IH, Ly LV, Jordanova ES et al (2011) Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci 52:643-650
30. Herwig MC, Grossniklaus HE (2011) Role of macrophages in uveal melanoma. Expert Rev Ophthalmol 6:405-407
31. Steidl C, Lee T, Shah SP et al (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362:875-885
32. Zaki MA, Wada N, Ikeda J et al (2011) Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch 459:361-366
33. Tzankov A, Matter MS, Dirnhofer S (2010) Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 77:301-308
34. Sanchez-Espiridion B, Martin-Moreno AM, Montalban C et al (2012) Immunohistochemical markers for tumor associated macrophages andsurvival in advanced classical Hodgkin lymphoma. Haematologica 97(7):1080-1084
35. Azambuja D, Natkunam Y, Biasoli I et al (2012) Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 23:736-742
36. Kamper P, Bendix K, Hamilton-Dutoit S et al (2011) Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 96:269-276
37. Canioni D, Salles G, Mounier N et al (2008) High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 26:440-446
38. Wada N, Zaki MA, Hori Y, Osaka Lymphoma Study Group et al (2012) Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 60:313-319
39. Hasselblom S, Hansson U, Sigurdardottir M et al (2008) Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int 58:529-532
40. Falini B, Flenghi L, Pileri S et al (1993) PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. Am J Pathol 142:1359-1372
41. Pulford KA, Rigney EM, Micklem KJ et al (1989) KP1: a new monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue sections. J Clin Pathol 42:414-421
42. Lau SK, Chu PG, Weiss LM (2004) CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol 122:794-801
43. Buechler C, Ritter M, Orsó E et al (2000) Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 67:97-103
44. Harris JA, Jain S, Ren Q et al (2012) CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol 7:12
45. Pappa C, Miyakis S, Tsirakis G et al (2007) Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma. Cytokine 37:171-175
46. Urbańska-RyÅ H, Wiersbowska A, Stepień H, Robak T (2000) Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma. Eur Cytokine Netw 11:443-451
47. Clear AJ, Lee AM, Calaminici M et al (2010) Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. Blood 115:5053-5056